The comorbidity and co-medication profile of patients with progressive supranuclear palsy.
Stephan GretenFlorian WegnerIda JensenLea KreySophia RogozinskiMeret FehringJohanne HeineJohanna Doll-LeeMonika Pötter-NergerMolly ZeitzschelKeno HagenaDavid J PedrosaCarsten EggersKatrin BürkClaudia TrenkwalderInga ClausTobias WarneckePatrick SüßJürgen WinklerDoreen GruberFlorin GandorDaniela BergSteffen PaschenJoseph ClassenElmar H PinkhardtJan KassubekWolfgang H JostLars TöngesAndrea A KühnJohannes SchwarzOliver PetersEman DashtiJosef PrillerEike J SpruthPatricia KrauseAnnika SpottkeAnja SchneiderAline BeyleOkka KimmichMarkus DonixRobert HaussmannMoritz BrandtElisabeth DinterJens WiltfangBjörn H SchottInga ZerrMathias BährKatharina BuergerDaniel JanowitzRobert PerneczkyBoris-Stephan RauchmannEndy WeidingerJohannes LevinSabrina KatzdoblerEmrah DüzelWenzel GlanzStefan TeipelIngo KilimannJohannes PrudloThomas GasserKathrin BrockmannDaniel C HoffmannThomas KlockgetherOlaf KrauseJohannes HeckGünter U HöglingerMartin KlietzPublished in: Journal of neurology (2023)
PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.